Physician profile
Allison Lou Sharp
NPI 1821385659
$1,806.28
in general payments reported to CMS, 2019-2025
19 companies · $34.41 in 2025
The $34.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $124 · 2021: $144 · 2022: $369 · 2023: $370 · 2024: $97.18 · 2025: $34.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $393.93 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $287.69 | 2019-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $198.62 | 2019-2023 | Breztri |
| Abbvie INC. | $191.93 | 2022-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $170.46 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.68 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.37 | 2019-2022 | |
| Pfizer INC. | $82.96 | 2019-2024 | |
| Astellas Pharma US INC | $39.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.39 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $27.87 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $21.46 | 2023 | |
| Boston Scientific Corporation | $20.24 | 2025 | General - Embolics |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.95 | 2022 | |
| Amgen INC. | $14.20 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14.13 | 2019 | |
| Mylan Specialty L.P. | $12.14 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.